nach oben

World Journal of Urology

Erschienen in:

01.02.2014 | Original Article

Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma

verfasst von: Jinsung Park, Sejun Park, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn

Erschienen in: World Journal of Urology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To elucidate the reasons for conflicting results regarding the prognostic significance of tumor location in upper tract urothelial carcinoma (UTUC), we analyzed the stage-specific impact of tumor location on oncological outcomes following radical nephroureterectomy (RNU).

Methods

Data from 392 patients who underwent RNU with curative intent between 1991 and 2010 were reviewed. Prognostic impact of tumor location and various clinicopathological factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Kaplan–Meier and Cox regression analyses at each pathological stage. Tumor location was classified as renal pelvis or ureter, and pT3 tumors were further stratified as invading the renal parenchyma or peripelvic or periureteral fat.

Results

In stage-specific analysis, tumor location did not have prognostic significance in patients with ≤pT2 tumors, whereas RFS and CSS rates were significantly lower in patients with pT3 ureteral tumors than renal pelvic tumors. Subgroup analysis showed that RFS and CSS rates were significantly higher for pT3 tumors invading the renal parenchyma than the peripelvic or periureteral fat. On multivariate analysis in pT3 tumors adjusting other clinicopathological parameters, tumor location remained significant predictors for both RFS and CSS. Compared with tumors invading renal parenchyma, tumors invading peripelvic fat or periureteral fat were associated with about 3.5 times higher risk for cancer-specific mortality (p < 0.05).

Conclusions

Location-dependent survival difference exists only in patients with pT3 UTUC. Conflicting institutional results regarding tumor location in UTUC may be due to difference in the proportions of parenchymal versus peripelvic fat invasion in pT3 pelvic tumors.

Raman JD, Messer J, Sielatycki JA, Hollenbeak CS (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA 1973–2005. BJU Int 107:1059–1064PubMedCrossRef

Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W et al (2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol 29:487–494PubMedCrossRef

Ouzzane A, Colin P, Ghoneim TP, Zerbib M, De La Taille A, Audenet F et al (2013) The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol 31:189–197PubMedCrossRef

Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A et al (2007) Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 110:1715–1722PubMedCrossRef

Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS et al (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253PubMedCrossRef

Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594–601PubMedCrossRef

Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D et al (1999) Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre rare cancer network study. Eur J Cancer 35:738–743PubMedCrossRef

Park S, Hong B, Kim CS, Ahn H (2004) The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 171:621–625PubMedCrossRef

Park J, Ha SH, Min GE, Song C, Hong B, Hong JH, Kim CS et al (2009) The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 182:894–899PubMedCrossRef

10.

Akdogan B, Dogan HS, Eskicorapci SY, Sahin A, Erkan I, Ozen H (2006) Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol 176:48–52PubMedCrossRef

11.

Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M et al (2007) Behavior of urothelial carcinoma with respect to anatomical location. J Urol 177:1715–1720PubMedCrossRef

12.

Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580PubMedCrossRef

13.

Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef

14.

Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef

15.

Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Widmer H et al (2010) Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int 105:799–804PubMedCrossRef

16.

Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in Urothelial Carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef

17.

Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA et al (2012) Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer 13:1083–1088CrossRef

18.

Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–13PubMedCrossRef

19.

Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584–594PubMedCrossRef

20.

Yoshimura K, Arai Y, Fujimoto H, Nishiyama H, Ogura K, Okino T, Ogawa O (2002) Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma. Cancer 94:3150–3156PubMedCrossRef

21.

Wu CF, Pang ST, Chen CS, Chuang CK, Chen Y, Lin PY (2007) The impact factors on prognosis of patients with pT3 upper urinary tract transitional cell carcinoma. J Urol 178:446–450PubMedCrossRef

22.

Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, Ahn H (2009) Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 27:277–283PubMedCrossRef

23.

Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef

24.

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M et al (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract Urothelial Carcinoma following radical surgery. Eur Urol 62:677–684PubMedCrossRef

25.

Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E et al (2012) Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. Eur Urol 62:224–231PubMedCrossRef

26.

Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E et al (2009) Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1,363 patients. BJU Int 103:307–311PubMedCrossRef

27.

Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W et al (2012) Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 30:666–672PubMedCrossRef

28.

Mitra AP, Datar RH, Cote RJ (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 24:5552–5564PubMedCrossRef

29.

Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N et al (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23:2903–2910PubMedCrossRef

30.

Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M et al (2012) Prognostic factors in upper urinary tract Urothelial Carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114PubMedCrossRef

Titel: Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma
verfasst von: Jinsung Park
Sejun Park
Cheryn Song
Jun Hyuk Hong
Choung-Soo Kim
Hanjong Ahn
Publikationsdatum: 01.02.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 1/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1073-8

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

The Urological Dyna-CT: ex vivo feasibility study of interventional cross-sectional imaging in the endourological operation room

Robotic-assisted laparoendoscopic single-site radical nephrectomy: first experience with the novel Da Vinci single-site platform

The use of a ureteral access sheath does not improve stone-free rate after ureteroscopy for upper urinary tract stones